Log in
Lost password
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nasdaq  >  Impax Laboratories Inc    IPXL

News SummaryMost relevantAll newsSector news 

Impax Laboratories Inc : Impax Laboratories to Present at the UBS Global Healthcare Conference

05/20/2013 | 07:35am US/Eastern

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the UBS Global Healthcare Conference on Wednesday, May 22, at 9:00 a.m. Eastern Standard Time. The conference will be held at the Sheraton New York Hotel.

Individuals may listen to the live or an archived presentation made at the conference, which will be posted in the investor relations section of the Company's web site at www.impaxlabs.com. This presentation will be archived on the Company's web site for 30 days.

About Impax Laboratories, Inc.

Impax Laboratories, Inc. (Impax) is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products. Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through the Impax Pharmaceuticals division. Additionally, where strategically appropriate, Impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies, such as injectables, nasal sprays, inhalers, patches, creams and ointments. For more information, please visit the Company's Web site at: www.impaxlabs.com.

Impax Laboratories, Inc.
Mark Donohue, 215-558-4526
Investor Relations and Corporate Communications

© Business Wire 2013
React to this article
09/03DJHayman Capital's Kyle Bass Vows to Continue Drug-Patent Challenges
09/03DJHayman Capital's Kyle Bass Vows to Continue Drug-Patent Challenges
08/20 IMPAX LABORATORIES : Announces Sale of Daraprim® to Turing Pharmaceuticals AG
08/20 IMPAX LABORATORIES : Turing Pharmaceuticals AG Acquires U.S. Marketing Rights to..
08/11 IMPAX LABORATORIES : Turing Pharma Acquires Daraprim Marketing Rights in US from..
08/10 IMPAX LABORATORIES : Management's Discussion and Analysis of Results of Operatio..
08/10 IMPAX LABORATORIES : Results of Operations and Financial Condition, Regulation F..
08/10 IMPAX LABORATORIES : Labs reports 2Q loss
08/10 IMPAX LABORATORIES : Announces Sale of Daraprim® to Turing Pharmaceuticals AG
08/05 IMPAX LABORATORIES : Entry into a Material Definitive Agreement, Creation of a D..
Duration : Period :
Impax Laboratories Inc Technical Analysis Chart | IPXL | US45256B1017 | 4-Traders
Income Statement Evolution
More Financials